• 7
    Apr
  • Bronchodilating Effect of Intravenous Magnesium Sulfate in Acute Severe Bronchial Asthma: RESULTS

Patient characteristics are listed in Table 1. The changes in FEV, during MgS04 infusion and during albuterol inhalation on two consecutive days are shown in Figure 1.

On day 1 as well as on day 2, there was a significant (p<0.05) improvement in FEV1 after MgS04 infusion, as well as a subjective improvement of dyspnea (five out of six patients) and of wheezes (five out of six patients) (Table 2).

FIGURE 1. Evolution of FEV, after MgSO< infusion and after beta agonist inhalation on two consecutive days (day 1, squares; day 2, triangles).

Thirty minutes after the end of the MgS04 infusion, there was a drop in FEV, in all patients, but FEV, did not reach the baseline values before MgS04 adminis­tration (p<0.05). Inhalation of albuterol, 30 minutes after ending the MgS04 infusion, resulted again in a significant (p<0.05) improvement of FEV, in all patients, with subjective and auscultatory improve­ment in all six patients, on both days. This improve­ment in FEV, was significantly more pronounced than the FEV, improvement after MgS04 infusion (p<0.02). Although some patients (eg, patients 1 and 4) showed variable responses of FEV, improvement on two consecutive days after MgS04 infusion, as a group there was no significant difference in FEV, improvement on day 1 compared with day 2. cialis soft tabs

Table 1—Patient Characteristics and Evolution of FEVl after MgS04 Infusion and after Beta-agonist Inhalation on Two Consecutive Days

Day

FEV, in Liters

FEV, in Liters

FEV, Improvement

Subject,

of

(and in
%
Predicted) FEV, in Liters FEV,
Improvement (and in
%
Predicted)

FEV, in Liters

in
%
after

Sex, Age (yr)
Study

before Mg

after Mg

in
%
after Mg

before
Betas-agonist after Beta2-agonist

Betas-agonist

1,F,49

1

1.12 (40)

1.25

12

1.16 (41)

1.94

67

2

1.16 (42)

1.73

49

1.34 (48)

2.36

76

2,M,60

1

0.56 (17)

0.71

27

0.70 (21)

1.12

60

2

0.64 (19)

0.78

22

0.66 (20)

1.35

104

3,M,45

1

1.13 (29)

1.28

13

1.23 (31)

1.54

25

2

1.92 (49)

2.30

20

2.19 (56)

2.49

14

4,F,55

1

0.82 (32)

1.01

23

0.97 (38)

1.28

32

2

0.56 (22)

1.01

80

0.79 (31)

1.31

66

5,F,46

1

0.47 (16)

1.09

132

0.8 (27)

1.44

80

2

1.07 (36)

1.40

31

1.05 (35)

*.33

27

6,F,24

1

0.88 (25)

1.50

70

1.32 (38)

2.21

67

2

1.13 (36)

1.65

46

1.37 (42)

2.30

68

Serum Mg concentrations significantly increased from 0.87 ±0.04 mmol/L before to 1.95 ±0.2 mmol/L after the MgS04 infusion, and had returned to baseline values 24 h later.

Table 2—Evolution of Clinical Signs and Symptoms and Occurrence of Adverse Effects During MgS04 Infusion

Subjects,

Day of

Improvement

Sex, Age (yr)
Study

Wheezing

of Dyspnea

Adverse Effects

I,F,49

1

S

• •
-t

Local burn

2

1/1/1/
toO

• • 4

…II

2,M,60

1

SS

. • 4

Flush

2

/

Flush, local burn

3,M,45

1

SS

. •
.t

…11

2

//

..
.t

.. .11

4,F,55

1

/

..
.t

Local burn

2

1/^1/
toO

Local burn

5,F,46

1

2

…II …II

…II …II

…II …II

6,F,24

1

• • 4

Flush

2

1/1/

Flush

The Mg concentrations in red blood cells did not significantly differ after the MgS04 infusion. There were no differences in heart rate or blood pressure during MgS04 infusion or during albuterol inhalation. Side effects which occurred during MgS04 infusion are listed in Table 2; local burn at the perfusion site was noted by three patients and hot flushes in two. Both side effects were well tolerated and were limited to the infusion period.
canadian antibiotics

Online Pharmacy